Services
Articles
Advancing Cell Therapy Development with Integrated Analytical and Process Strategies
Discover how integrated analytical and process development can accelerate cell therapy development, reduce risk, and support commercialization.
From Clinical Supply to Commercial-Ready, Inspection-Ready Manufacturing
Kincell Bio produces cell therapies in our GMP manufacturing facilities with the pace early programs demand and the rigor commercialization requires. We utilize standardized platforms wherever possible, reduce manual variability through automated workflows whenever possible, and maintain pre-approval inspection (PAI)-ready facilities every day. This rigor provides the confidence that you can meet rising regulatory expectations and build a resilient supply strategy from Phase I through commercial supply.
Two Sites. One Scalable, Inspection-Ready Manufacturing Network
Kincell Bio’s two-site manufacturing network supports cell therapy programs from early clinical development through commercialization. Standardized platforms, aligned quality systems, and coordinated processes enable efficient tech transfer between facilities while providing scalable GMP capacity and built-in supply continuity.
Early Development & Clinical Supply
Kincell’s Gainesville facility focuses on early-phase CMC development and clinical manufacturing, helping innovators translate promising science into GMP-ready processes.
- Early-phase CMC development and process optimization
- Preclinical and early clinical GMP manufacturing
- Analytical development and characterization support
- Platform-based process development to enable future scale-up or scale-out
- Aligned GMP systems that enable seamless transfer to late-stage manufacturing
Pivotal & Commercial Manufacturing
Our Research Triangle Park facility supports late-stage clinical development and commercial readiness with scalable GMP manufacturing infrastructure.
- Pivotal and registrational clinical manufacturing
- Commercial-scale cell therapy production capabilities
- Robust QC, QA, and batch release operations
- Inspection-ready quality systems supporting regulatory approval
- Manufacturing capacity designed to support long-term commercial supply
Kincell Bio’s Clinical & Commercial
GMP Manufacturing
From the earliest phases of a cell therapy program, we design processes and analytical strategies with clinical and commercial supply at the forefront.
Early-Phase Acceleration
Early-Phase Acceleration
Target Product Profiles and risk-based strategies aligned with IND and long-term commercial goals guide our approach to proof of concept and early-phase clinical manufacturing.
Late-Phase Development
Commercialization & Commercial Supply
GMP Manufacturing Strategies Tailored for Autologous and Allogeneic Cell Therapies
Autologous and allogeneic cell therapies require tailored GMP manufacturing strategies to ensure reproducible, high-quality drug products that meet the program’s needs.
Autologous Cell Therapies
Autologous cell therapy manufacturing follows a one-batch, one-patient model, where success depends on repeatable processes. The focus is on scaling out the ability to produce many patient-specific batches efficiently by reducing manual touchpoints, strengthening chain-of-identity controls, improving in-process analytics, and enabling automation to minimize variability, errors, and turnaround time.
Allogeneic Cell Therapies
Allogeneic cell therapy manufacturing relies on batch-based scale-up to increase yield and serve more patients per run. Success depends on robust cell banking, scalable expansion platforms, tightly controlled critical process parameters, and process characterization that supports comparability, consistency, and utilization of commercial-ready automation wherever possible.
Industry-Leading Autologous & Allogenic GMP Manufacturing
Kincell Bio brings deep experience across a broad range of autologous and allogenic cell therapy programs, positioning us to support our clients wherever their science leads. Whether supplying preclinical or commercial drug products, we ensure a reliable, high-quality supply.
- CAR-T
- CAR-M
- CAR-NK
- TCR-T
- Differentiated iPSC
- TRegs
- Natural killer (NK)
Facilities & Teams Supporting the Entire Product Lifecycle
Kincell provides GMP manufacturing services across the full cell therapy lifecycle, with our Gainesville, FL, USA facility focused on early CMC and clinical supply, and our Research Triangle Park, NC, USA facility emphasizing pivotal and commercial manufacturing. Together, the two facilities provide scalable and redundant GMP capacity, robust analytics, and expansion-ready infrastructure to ensure long-term program continuity and supply reliability.
Bringing Cell Therapy Discoveries to Life
Kincell Bio develops and delivers tomorrow’s cell therapy cures by integrating comprehensive, end-to-end capabilities across the full product lifecycle, with deep expertise spanning a broad range of autologous and allogeneic cell therapy modalities.
Integrated Services
Articles
Reduce the Time and Cost of Cell Therapy Analytical Method Development with Design-of-Experiment (DoE)
Application of design-of-experiment (DoE) methodology to the development of cell-based assays for cell therapies can dramatically reduce the time and cost of...
Videos
Turning Promise Into Cures
In this video, hear how Kincell Bio’s team balances speed, quality, and collaboration, from pre-IND development to the moment a patient is...
Talk to an expert
Turning Cell Therapy Innovation Into Patient Impact
Leveraging our science-first expertise and right-first-time quality, partner with Kincell Bio to advance your cell therapy from concept to commercialization.
"*" indicates required fields